FDA warned www.buynetmeds.com for selling unapproved, misbranded tapentadol and semaglutide drugs, including injectables, to U.S. consumers online.
What happened
FDA reviewed the website www.buynetmeds.com and found it offered tapentadol opioid products and semaglutide products, including injectables, for sale to U.S. consumers. FDA said the products are unapproved new drugs and are misbranded, and that prescription drugs were offered without a prescription. The letter cited website claims describing the products as medicines to treat pain, type 2 diabetes, and weight reduction.
What FDA found
The website offered tapentadol and semaglutide drug products for sale to U.S. consumers without FDA-approved applications.
FD&C Act sections 301(d) and 505(a) [21 U.S.C. §§ 331(d), 355(a)]The prescription drugs lacked adequate directions for use by a layperson, so FDA deemed them misbranded.
FD&C Act section 502(f)(1) [21 U.S.C. § 352(f)(1)]The website offered prescription drugs for sale without requiring a prescription, misbranding them while held for sale.
FD&C Act sections 503(b)(1) and 301(k) [21 U.S.C. §§ 353(b)(1), 331(k)]The website introduced misbranded and unapproved drugs into interstate commerce.
FD&C Act section 301(a) [21 U.S.C. § 331(a)]
What FDA wants
FDA asks the company to stop offering any unapproved and misbranded drugs for sale to U.S. consumers. It must respond in writing within 15 working days describing corrective steps and preventing recurrence.
Who should pay attention
- U.S. consumers who buy prescription drugs online
- online pharmacies selling to U.S. customers
- companies distributing tapentadol or semaglutide products
This is a summary. Read the original letter on fda.gov.